Phreesia, Inc. (NYSE:PHR) SVP Sells $344,995.20 in Stock

Phreesia, Inc. (NYSE:PHRGet Free Report) SVP David Linetsky sold 11,616 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $29.70, for a total transaction of $344,995.20. Following the transaction, the senior vice president now owns 218,135 shares of the company’s stock, valued at $6,478,609.50. The trade was a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

David Linetsky also recently made the following trade(s):

  • On Friday, February 7th, David Linetsky sold 300 shares of Phreesia stock. The stock was sold at an average price of $29.52, for a total transaction of $8,856.00.
  • On Wednesday, February 5th, David Linetsky sold 720 shares of Phreesia stock. The shares were sold at an average price of $29.50, for a total transaction of $21,240.00.
  • On Wednesday, January 29th, David Linetsky sold 500 shares of Phreesia stock. The shares were sold at an average price of $29.68, for a total transaction of $14,840.00.
  • On Monday, January 27th, David Linetsky sold 11,685 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total transaction of $321,103.80.
  • On Wednesday, December 18th, David Linetsky sold 24 shares of Phreesia stock. The shares were sold at an average price of $25.38, for a total transaction of $609.12.
  • On Monday, December 16th, David Linetsky sold 35 shares of Phreesia stock. The shares were sold at an average price of $24.88, for a total transaction of $870.80.
  • On Wednesday, December 11th, David Linetsky sold 11,853 shares of Phreesia stock. The shares were sold at an average price of $24.85, for a total transaction of $294,547.05.

Phreesia Price Performance

NYSE:PHR opened at $29.99 on Wednesday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -20.40 and a beta of 0.96. The firm’s 50-day simple moving average is $26.93 and its 200 day simple moving average is $23.68. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74.

Phreesia (NYSE:PHRGet Free Report) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same period last year, the firm earned ($0.58) earnings per share. Phreesia’s revenue for the quarter was up 16.6% compared to the same quarter last year. As a group, sell-side analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On Phreesia

Several hedge funds have recently bought and sold shares of the company. Invesco Ltd. increased its holdings in Phreesia by 0.9% in the 4th quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock valued at $1,013,000 after buying an additional 357 shares during the period. NewEdge Advisors LLC increased its holdings in Phreesia by 12.1% in the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock valued at $107,000 after buying an additional 459 shares during the period. Johnson Financial Group Inc. increased its holdings in Phreesia by 381.3% in the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after buying an additional 896 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Phreesia by 3.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after buying an additional 905 shares during the period. Finally, MetLife Investment Management LLC increased its holdings in Phreesia by 3.8% in the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock valued at $701,000 after buying an additional 1,120 shares during the period. 92.10% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PHR has been the topic of several research analyst reports. KeyCorp increased their price objective on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, January 8th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Truist Financial increased their price objective on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research report on Friday, January 10th. Finally, JMP Securities reissued a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Phreesia presently has an average rating of “Buy” and an average price target of $31.15.

Check Out Our Latest Stock Analysis on Phreesia

About Phreesia

(Get Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

See Also

Insider Buying and Selling by Quarter for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.